News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


HTTP Technology, Inc. Announces Hospital Tests for Revolutionary Aid for Cancer Detection (PR Newswire)...Tests are due to start in August in the leading UK cancer treatment hospital....... now being expanded to analyse MRI scans of both the brain and heart....- Jul 05 8:59 AM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/prnews/010705/lnth004.html

Posted on: 07/05/2001

"Yahoo - HTTP Technology, Inc. Announces Hospital Tests for Revolutionary Aid for Cancer Detection"
Yahoo! Finance Finance Home - Yahoo! - Help
PR Newswire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
HTTP.OB
6.6
+0.0
delayed 20 mins - disclaimer

Thursday July 5, 8:59 am Eastern Time

Press Release

SOURCE: HTTP Technology, Inc.

HTTP Technology, Inc. Announces Hospital Tests for Revolutionary Aid for Cancer Detection

LONDON, July 5 /PRNewswire/ -- HTTP Technology, Inc. (OTC Bulletin Board: HTTP - news), a US company based in London, today announced the commencement of hospital testing of its newly developed Medicsight system. The Medicsight software currently analyses Computerised Axial Tomography (CAT) scans of the lungs and detects suspected cancerous nodules.

Tests are due to start in August in the leading UK cancer treatment hospital. In addition, due to the company's unique relationship with the Zayed Institute for Research & Technology in the United Arab Emirates, the system will be tested at the Sheikh Khalifa and Tawam hospitals in Abu Dhabi, under the supervision of Professor Farhan Bakir. "Professor Bakir is one of the most distinguished physicians in the Middle East. His joining of the HTTP medical advisory board is another important practical example of our relationship with the Zayed Institute," said Stefan Allesch-Taylor, Chairman of HTTP Technology.

The Medicsight system analyses scans of the lungs using 3-D CAT data and automatically detects and highlights suspected cancerous nodules. The detection of these nodules is in itself extremely difficult as currently all detection is carried out with the naked eye. "It is realistic to expect a very good radiologist to detect abnormalities at around the 10 mm level. Couple that with the sheer number of scan slices, between 32 and 55 per patient, and the ever increasing number of patients, and there can be no controversy in saying that there is much room for improving this method," said Dr. John Costello, Chairman of the HTTP medical advisory board and a Director of Medicine at King's College Hospital.

The Medicsight system has two distinctive features. The first is the ability, using highly sophisticated methods, to actually detect abnormalities that are well beyond the scope of the human eye. "Finding an abnormality of 2mm is an amazing achievement," said David Whelbourn of HTTP's medical division, "but it is highly unlikely that any surgeon will instruct a biopsy for such a tiny abnormality. They would have to wait and see how it develops. What makes the Medicsight system so exciting is its classification capability. In other words, yes, the system will find tiny abnormalities, but equally importantly, using 10 different measurements, it will help the radiologist identify them as potentially life threatening."

The Medicsight system can be adapted to cover any organ of the body. "One of the reasons we chose to tackle the detection of pulmonary nodules first is the knowledge that if lung cancer can be detected early enough it can be cured, giving us a sense of urgency to get the Medicsight system in use as quickly as possible," said Dr. Costello.

The Medicsight system is now being expanded to analyse MRI scans of both the brain and heart. "Cardiovascular disease is a huge health threat which affects a significant number of people. We will be turning our full attention to deploying the Medicsight system so that it can assist in detecting the presence of this disease at the earliest time," said Dr. Mahmoud Barbir, a Consultant Cardiologist at the Royal Brompton and Harefield Hospital and member of the HTTP medical advisory board.

This software system is a product enhancement and, despite its phenomenal potential, does not require hardware investment.

Notes:

HTTP Technology, Inc. corporate information.

HTTP Technology, Inc. (OTC Bulletin Board: HTTP - news) is a company incorporated in Delaware in the United States with headquarters in London. An application has been submitted for the company to join the main NASDAQ National Market.

HTTP Technology, Inc. conceives, develops and commercialises innovative technologies that will set new standards for solving industry wide problems in their target markets.

The first of these proprietary technologies is an advanced data analysis, classification, modelling and prediction system called the Stochastic Perception Engine. HTTP is initially focusing on the medical, defence and environmental applications of the technology.

SOURCE: HTTP Technology, Inc.

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:HTTP Technology Inc (OTC BB:HTTP.OB - news)
Related News Categories: biotech, computers, networking, software

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740